Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Heart Circ Physiol ; 305(5): H651-66, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23792682

ABSTRACT

Reduced production of nitric oxide (NO) is one of the first indications of endothelial dysfunction and precedes overt cardiovascular disease. Increased expression of Arginase has been proposed as a mechanism to account for diminished NO production. Arginases consume l-arginine, the substrate for endothelial nitric oxide synthase (eNOS), and l-arginine depletion is thought to competitively reduce eNOS-derived NO. However, this simple relationship is complicated by the paradox that l-arginine concentrations in endothelial cells remain sufficiently high to support NO synthesis. One mechanism proposed to explain this is compartmentalization of intracellular l-arginine into distinct, poorly interchangeable pools. In the current study, we investigated this concept by targeting eNOS and Arginase to different intracellular locations within COS-7 cells and also BAEC. We found that supplemental l-arginine and l-citrulline dose-dependently increased NO production in a manner independent of the intracellular location of eNOS. Cytosolic arginase I and mitochondrial arginase II reduced eNOS activity equally regardless of where in the cell eNOS was expressed. Similarly, targeting arginase I to disparate regions of the cell did not differentially modify eNOS activity. Arginase-dependent suppression of eNOS activity was reversed by pharmacological inhibitors and absent in a catalytically inactive mutant. Arginase did not directly interact with eNOS, and the metabolic products of arginase or downstream enzymes did not contribute to eNOS inhibition. Cells expressing arginase had significantly lower levels of intracellular l-arginine and higher levels of ornithine. These results suggest that arginases inhibit eNOS activity by depletion of substrate and that the compartmentalization of l-arginine does not play a major role.


Subject(s)
Arginase/metabolism , Arginine/metabolism , COS Cells/metabolism , Endothelium, Vascular/metabolism , Nitric Oxide Synthase Type III/metabolism , Animals , Aorta/cytology , Aorta/metabolism , Arginine/pharmacology , COS Cells/cytology , Cattle , Cell Line , Cells, Cultured , Chlorocebus aethiops , Citrulline/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Models, Animal , Nitric Oxide/metabolism , Ornithine/metabolism
2.
Pulm Circ ; 3(1): 58-67, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23662175

ABSTRACT

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary arterial resistance and vessel remodeling. Patients living with human immunodeficiency virus-1 (HIV-1) have an increased susceptibility to develop severe pulmonary hypertension (PH) irrespective of their CD4+ lymphocyte counts. While the underlying cause of HIV-PAH remains unknown, the interaction of HIV-1 proteins with the vascular endothelium may play a critical role in HIV-PAH development. Hypoxia promotes PH in experimental models and in humans, but the impact of HIV-1 proteins on hypoxia-induced pulmonary vascular dysfunction and PAH has not been examined. Therefore, we hypothesize that the presence of HIV-1 proteins and hypoxia synergistically augment the development of pulmonary vascular dysfunction and PH. We examined the effect of HIV-1 proteins on pulmonary vascular resistance by measuring pressure-volume relationships in isolated lungs from wild-type (WT) and HIV-1 Transgenic (Tg) rats. WT and HIV-1 Tg rats were exposed to 10% O2 for four weeks to induce experimental pulmonary hypertension to assess whether HIV-1 protein expression would impact the development of hypoxia-induced PH. Our results demonstrate that HIV-1 protein expression significantly increased pulmonary vascular resistance (PVR). HIV-1 Tg mice demonstrated exaggerated pulmonary vascular responses to hypoxia as evidenced by greater increases in right ventricular systolic pressures, right ventricular hypertrophy and vessel muscularization when compared to wild-type controls. This enhanced PH was associated with enhanced expression of HIF-1α and PCNA. In addition, in vitro studies reveal that medium from HIV-infected monocyte derived macrophages (MDM) potentiates hypoxia-induced pulmonary artery endothelial proliferation. These results indicate that the presence of HIV-1 proteins likely impact pulmonary vascular resistance and exacerbate hypoxia-induced PH.

3.
J Endocrinol ; 210(3): 271-84, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21642378

ABSTRACT

Rather than being a constitutive enzyme as was first suggested, endothelial nitric oxide synthase (eNOS) is dynamically regulated at the transcriptional, posttranscriptional, and posttranslational levels. This review will focus on how changes in eNOS function are conferred by various posttranslational modifications. The latest knowledge regarding eNOS targeting to the plasma membrane will be discussed as the role of protein phosphorylation as a modulator of catalytic activity. Furthermore, new data are presented that provide novel insights into how disruption of the eNOS dimer prevents eNOS uncoupling and the production of superoxide under conditions of elevated oxidative stress and identifies a novel regulatory region we have termed the 'flexible arm'.


Subject(s)
Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Amino Acid Sequence , Animals , Biopterins/analogs & derivatives , Biopterins/metabolism , Cell Membrane/metabolism , Dimerization , Enzyme Activation , Humans , Models, Molecular , Molecular Dynamics Simulation , Molecular Sequence Data , Nitric Oxide Synthase Type III/chemistry , Phosphorylation , Protein Processing, Post-Translational , Protein Structure, Quaternary , Serine/metabolism , Threonine/metabolism , Tyrosine/metabolism
4.
J Biol Chem ; 285(46): 35479-87, 2010 Nov 12.
Article in English | MEDLINE | ID: mdl-20826796

ABSTRACT

Oxygen toxicity is the most severe side effect of oxygen therapy in neonates and adults. Pulmonary damage of oxygen toxicity is related to the overproduction of reactive oxygen species (ROS). In the present study, we investigated the effect of hyperoxia on the production of peroxynitrite in pulmonary artery endothelial cells (PAEC) and mouse lungs. Incubation of PAEC under hyperoxia (95% O(2)) for 24 h resulted in an increase in peroxynitrite formation. Uric acid, a peroxynitrite scavenger, prevented hyperoxia-induced increase in peroxynitrite. The increase in peroxynitrite formation is accompanied by increases in nitric oxide (NO) release and endothelial NO synthase (eNOS) activity. We have previously reported that association of eNOS with ß-actin increases eNOS activity and NO production in lung endothelial cells. To study whether eNOS-ß-actin association contributes to increased peroxynitrite production, eNOS-ß-actin interaction were inhibited by reducing ß-actin availability or by using a synthetic peptide (P326TAT) containing a sequence corresponding to the actin binding site on eNOS. We found that disruption of eNOS-ß-actin interaction prevented hyperoxia-induced increases in eNOS-ß-actin association, eNOS activity, NO and peroxynitrite production, and protein tyrosine nitration. Hyperoxia failed to induce the increases in eNOS activity, NO and peroxynitrite formation in COS-7 cells transfected with plasmids containing eNOS mutant cDNA in which amino acids leucine and tryptophan were replaced with alanine in the actin binding site on eNOS. Exposure of mice to hyperoxia resulted in significant increases in eNOS-ß-actin association, eNOS activity, and protein tyrosine nitration in the lungs. Our data indicate that increased association of eNOS with ß-actin in PAEC contributes to hyperoxia-induced increase in the production of peroxynitrite which may cause nitrosative stress in pulmonary vasculature.


Subject(s)
Actins/metabolism , Endothelial Cells/metabolism , Lung/metabolism , Nitric Oxide Synthase Type III/metabolism , Peroxynitrous Acid/biosynthesis , Actins/genetics , Animals , COS Cells , Cells, Cultured , Chlorocebus aethiops , Endothelial Cells/cytology , Endothelial Cells/drug effects , Hyperoxia/physiopathology , Immunoblotting , Lung/blood supply , Lung/drug effects , Male , Mice , Mice, Inbred C57BL , Microscopy, Confocal , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/genetics , Oligopeptides/pharmacology , Oxygen/pharmacology , Protein Binding/drug effects , Pulmonary Artery/cytology , RNA Interference , Superoxides/metabolism , Swine , Tyrosine/metabolism
5.
Free Radic Biol Med ; 49(2): 159-70, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20353820

ABSTRACT

Previous studies have shown that acute increases in oxidative stress induced by the addition of hydrogen peroxide (H(2)O(2)) can increase endothelial nitric oxide synthase (eNOS) catalytic activity via an increase in the phosphorylation of eNOS at serine 1177. However, it is unclear how increased H(2)O(2) affects nitric oxide (NO) signaling when endothelial cells are exposed to biomechanical forces. Thus, the purpose of this study was to evaluate the acute effects of H(2)O(2) on NO signaling in the presence or absence of laminar shear stress. We found that acute sustained increases in cellular H(2)O(2) levels in bovine aortic endothelial cells did not alter basal NO generation but the NO produced in response to shear stress was significantly increased. This amplification in NO signaling was found to correlate with an H(2)O(2)-induced increase in eNOS localized to the plasma membrane and an increase in total caveolin-1 protein levels. We further demonstrated that overexpressing caveolin-1 increased eNOS localized to the plasma membrane again without altering total eNOS protein levels. We also found that caveolin-1 overexpression increased NO generation in response to shear stress but only in the presence of H(2)O(2). Conversely, depleting caveolin-1 with an siRNA decreased eNOS localized to the plasma membrane and abolished the enhanced NO generation. Finally, we found that expressing a caveolin-1 binding-site deletion mutant of eNOS in COS-7 cells decreased its plasma membrane localization and resulted in attenuated NO production in response to calcium activation. In conclusion, we have identified a new role for caveolin-1 in enhancing eNOS trafficking to the plasma membrane that seems to be involved in priming eNOS for flow-mediated activation under conditions of oxidative stress. To our knowledge, this is the first report that H(2)O(2) modulates eNOS activity by altering its subcellular location and that caveolin-1 can play a stimulatory role in NO signaling.


Subject(s)
Caveolin 1/metabolism , Endothelium, Vascular/drug effects , Enzyme Activation , Hydrogen Peroxide/pharmacology , Nitric Oxide Synthase Type III/metabolism , Shear Strength , Animals , Binding Sites/genetics , COS Cells , Cattle , Caveolin 1/genetics , Cell Membrane/drug effects , Cell Membrane/metabolism , Chlorocebus aethiops , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Enzyme Activation/drug effects , Nitric Oxide/genetics , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/genetics , Protein Transport/drug effects , Protein Transport/genetics , RNA, Small Interfering/genetics , Sequence Deletion/genetics , Signal Transduction/drug effects , Signal Transduction/genetics , Transgenes/genetics
6.
J Biol Chem ; 285(7): 4319-27, 2010 Feb 12.
Article in English | MEDLINE | ID: mdl-19946124

ABSTRACT

Protein-protein interactions represent an important post-translational mechanism for endothelial nitric-oxide synthase (eNOS) regulation. We have previously reported that beta-actin is associated with eNOS oxygenase domain and that association of eNOS with beta-actin increases eNOS activity and nitric oxide (NO) production. In the present study, we found that beta-actin-induced increase in NO production was accompanied by decrease in superoxide formation. A synthetic actin-binding sequence (ABS) peptide 326 with amino acid sequence corresponding to residues 326-333 of human eNOS, one of the putative ABSs, specifically bound to beta-actin and prevented eNOS association with beta-actin in vitro. Peptide 326 also prevented beta-actin-induced decrease in superoxide formation and increase in NO and L-citrulline production. A modified peptide 326 replacing hydrophobic amino acids leucine and tryptophan with neutral alanine was unable to interfere with eNOS-beta-actin binding and to prevent beta-actin-induced changes in NO and superoxide formation. Site-directed mutagenesis of the actin-binding domain of eNOS replacing leucine and tryptophan with alanine yielded an eNOS mutant that exhibited reduced eNOS-beta-actin association, decreased NO production, and increased superoxide formation in COS-7 cells. Disruption of eNOS-beta-actin interaction in endothelial cells using ABS peptide 326 resulted in decreased NO production, increased superoxide formation, and decreased endothelial monolayer wound repair, which was prevented by PEG-SOD and NO donor NOC-18. Taken together, this novel finding indicates that beta-actin binding to eNOS through residues 326-333 in the eNOS protein results in shifting the enzymatic activity from superoxide formation toward NO production. Modulation of NO and superoxide formation from eNOS by beta-actin plays an important role in endothelial function.


Subject(s)
Actins/metabolism , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Superoxides/metabolism , Animals , COS Cells , Chlorocebus aethiops , Citrulline/metabolism , Humans , Immunoprecipitation , Mice , Mutagenesis, Site-Directed , Nitric Oxide Synthase Type III/chemistry , Nitric Oxide Synthase Type III/genetics , Peptides/chemical synthesis , Peptides/chemistry , Peptides/pharmacology , Protein Binding/drug effects , Protein Binding/physiology
7.
Am J Physiol Heart Circ Physiol ; 292(5): H2100-5, 2007 May.
Article in English | MEDLINE | ID: mdl-17259435

ABSTRACT

Studies in rat aorta have shown that the Na-K-2Cl cotransporter NKCC1 is activated by vasoconstrictors and inhibited by nitrovasodilators, contributes to smooth muscle tone in vitro, and is upregulated in hypertension. To determine the role of NKCC1 in systemic vascular resistance and hypertension, blood pressure was measured in rats before and after inhibition of NKCC1 with bumetanide. Intravenous infusion of bumetanide sufficient to yield a free plasma concentration above the IC(50) for NKCC1 produced an immediate drop in blood pressure of 5.2% (P < 0.001). The reduction was not prevented when the renal arteries were clamped, indicating that it was not due to a renal effect of bumetanide. Bumetanide did not alter blood pressure in NKCC1-null mice, demonstrating that it was acting specifically through NKCC1. In third-order mesenteric arteries, bumetanide-inhibitable efflux of (86)Rb was acutely stimulated 133% by phenylephrine, and bumetanide reduced the contractile response to phenylephrine, indicating that NKCC1 influences tone in resistance vessels. The hypotensive effect of bumetanide was proportionately greater in rats made hypertensive by a 7-day infusion of norepinephrine (12.7%, P < 0.001 vs. normotensive rats) but much less so when hypertension was produced by a fixed aortic coarctation (8.0%), again consistent with an effect of bumetanide on resistance vessels rather than other determinants of blood pressure. We conclude that NKCC1 influences blood pressure through effects on smooth muscle tone in resistance vessels and that this effect is augmented in hypertension.


Subject(s)
Blood Pressure/physiology , Muscle Contraction/physiology , Muscle, Smooth, Vascular/physiology , Sodium-Potassium-Chloride Symporters/metabolism , Vasoconstriction/physiology , Animals , Blood Pressure/drug effects , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Rats , Solute Carrier Family 12, Member 2 , Vascular Resistance/physiology , Vasoconstriction/drug effects
8.
Am J Physiol Lung Cell Mol Physiol ; 291(4): L811-9, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16728526

ABSTRACT

Human immunodeficiency virus (HIV)-1 causes lung disease by increasing the host's susceptibility to pathogens. HIV-1 also causes an increase in systemic oxidative/nitrosative stress, perhaps enhancing the deleterious effects of secondary infections. Here we examined the ability of HIV-1 proteins to increase lung oxidative/nitrosative stress after lipopolysaccharide (LPS) (endotoxin) administration in an HIV-1 transgenic mouse model. Lung oxidative/nitrosative stress biomarkers studied 3 and 6 h after LPS administration were as follows: lung edema, tissue superoxide, NO metabolites, nitrotyrosine, hydrogen peroxide, and bronchoalveolar lavage fluid (BALF) glutathione (GSH). Blood serum cytokine levels were quantified to verify immune function of our nonimmunocompromised animal model. Results indicate that 3 h after LPS administration, HIV-1 transgenic mouse lung tissue has significantly greater edema and superoxide. Furthermore, NO metabolites are significantly elevated in HIV-1 transgenic mouse BALF, lung tissue, and blood plasma compared with those of wild-type mice. HIV-1 transgenic mice also produce significantly greater lung nitrotyrosine and hydrogen peroxide than wild-type mice. In addition, HIV-1 transgenic mice produce significantly less BALF GSH than wild-type mice 3 h after LPS treatment. Without treatment, serum cytokine levels are similar for HIV-1 transgenic and wild-type mice. After treatment, serum cytokine levels are significantly elevated in both HIV-1 transgenic and wild-type mice. Therefore, HIV-1 transgenic mice have significantly greater lung oxidative/nitrosative stress after endotoxin administration than wild-type mice, independent of immune function. These results indicate that HIV-1 proteins may increase pulmonary complications subsequent to a secondary infection by altering the lung redox potential.


Subject(s)
HIV Infections/metabolism , Lipopolysaccharides/pharmacology , Lung/metabolism , Nitrates/metabolism , Nitrites/metabolism , Oxidative Stress/drug effects , Animals , Cytokines/metabolism , Glutathione/metabolism , HIV-1 , Hydrogen Peroxide/metabolism , Lung/drug effects , Mice , Mice, Transgenic , Nitrosation , Pulmonary Edema/chemically induced , Tyrosine/analogs & derivatives , Tyrosine/biosynthesis
9.
Am J Respir Cell Mol Biol ; 34(3): 314-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16284359

ABSTRACT

Alcohol abuse increases the incidence of acute respiratory distress syndrome and causes oxidative stress and cellular dysfunction in the lung. The mechanisms of ethanol (EtOH)-induced oxidative stress in the lung remain to be defined. Chronic alcohol ingestion has been associated with increased renin-angiotensin system (RAS) activity. Therefore, the current study investigated the ability of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, to modulate oxidative stress in the lung after chronic EtOH ingestion in a well-established rat model. Male Sprague-Dawley rats were fed liquid diets containing EtOH (36% of calories) or maltose-dextrin as an isocaloric substitution for EtOH (Control) for 6 wk. Selected animals were also treated with lisinopril (3 mg/liter) for 6 wk. Chronic EtOH ingestion increased bronchoalveolar lavage fluid glutathione disulfide levels and superoxide formation in lung parenchyma. These effects of EtOH were attenuated by lisinopril treatment. Chronic EtOH ingestion failed to increase ACE expression or angiotensin II levels in lung homogenates, but increased angiotensinogen, angiotensin II type 1 and type 2 receptor levels, and ACE activity. Chronic EtOH ingestion also increased the levels of the NADPH oxidase subunit, gp91phox, an effect that was attenuated by lisinopril, but had no effect on lung p22phox or p47phox levels. These findings suggest that EtOH-mediated RAS activation plays an important role in pulmonary oxidative stress and provide new insights into mechanisms by which EtOH causes oxidative stress in the lung and potential strategies of lung protection through ACE inhibition.


Subject(s)
Ethanol/pharmacology , Lung/drug effects , Membrane Glycoproteins/metabolism , NADPH Oxidases/metabolism , Superoxides/metabolism , Angiotensin II/metabolism , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensinogen/metabolism , Animals , Bronchoalveolar Lavage Fluid/chemistry , Ethanol/administration & dosage , Glutathione Disulfide/metabolism , Lisinopril/pharmacology , Lung/metabolism , Lung/pathology , Male , Membrane Transport Proteins/metabolism , NADPH Oxidase 2 , Oxidative Stress , Peptidyl-Dipeptidase A/biosynthesis , Phosphoproteins/metabolism , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1/metabolism , Receptor, Angiotensin, Type 2/metabolism , Renin-Angiotensin System/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...